Skip to content
TheChatArchiveThe Chat Archive
Claudeclaude-sonnet-4-20250514· AnthropicHugging Face LMArena Human Preference 140K

is it already settled if high LDL-C in mass lean hyper responders adopting a keto diet…

From a Chatbot Arena battleThe same person sent this prompt to two anonymous models at once. Compare it with Geminigemini-2.5-flash’s answer.
  1. User

    is it already settled if high LDL-C in mass lean hyper responders adopting a keto diet increases risk for CVD

  2. Claude Assistant

    No, it is absolutely NOT settled whether high LDL-C in Lean Mass Hyper-Responders (LMHRs) increases CVD risk. This is one of the most hotly debated and actively researched questions in modern lipidology and nutritional science.

    Here's the current state of knowledge:


    What We DON'T Know (The Big Unknowns)

    1. No Long-Term Outcome Data

    • Missing Evidence: There are no large-scale, long-term studies specifically tracking cardiovascular outcomes in LMHRs with very high LDL-C (300-500+ mg/dL) on ketogenic diets.
    • Timeline Issue: The LMHR phenotype has only been formally identified and studied in the last 5-10 years, so we lack decades of follow-up data.

    2. Conflicting Mechanistic Theories

    • Traditional View: High LDL-C = more atherogenic particles = higher plaque formation risk, regardless of metabolic context.
    • Lipid Energy Model (LEM): In LMHRs, high LDL-C reflects efficient fat energy trafficking, not pathological lipid accumulation. The particles may be "empty buses" delivering energy, not "garbage trucks" dumping cholesterol in arteries.

    Current Research Efforts

    1. The Lundquist Institute Study

    • What: Ongoing research specifically examining arterial plaque progression in LMHRs using advanced imaging (coronary calcium scores, CIMT).
    • Goal: Determine if LMHRs with extreme LDL-C elevation actually develop more atherosclerosis over time.
    • Status: Results are pending and eagerly awaited by the lipidology community.

    2. Citizen Science and Case Studies

    • Dave Feldman's Work: The engineer who identified the LMHR phenotype has been tracking his own and others' biomarkers, including advanced lipid testing and imaging.
    • Anecdotal Evidence: Many LMHRs report excellent cardiovascular health markers (low inflammation, good arterial flexibility, zero calcium scores) despite extreme LDL-C elevation, but this is not definitive proof.

    What We DO Know (Limited Evidence)

    1. LMHRs Often Have Excellent Metabolic Health

    • Low Triglycerides: Typically <70 mg/dL, often <50 mg/dL.
    • High HDL-C: Usually >80 mg/dL, often >100 mg/dL.
    • Low Inflammation: Often low CRP, excellent insulin sensitivity.
    • Good Blood Pressure: Typically normal or low.

    2. Traditional Risk Calculators May Not Apply

    • Framingham Risk Score: Designed for the general population, may overestimate risk in metabolically healthy individuals with isolated high LDL-C.
    • Context Matters: The same LDL-C level may carry different risks depending on insulin resistance, inflammation, and other factors.

    3. Some Reassuring Signals

    • Calcium Scores: Many LMHRs report calcium scores of 0 (no detectable plaque) despite years of very high LDL-C.
    • Advanced Lipid Testing: Some LMHRs show predominantly large, buoyant LDL particles (Pattern A) rather than small, dense particles (Pattern B).

    The Scientific Controversy

    The "High LDL = Bad" Camp

    • Position: LDL particles are necessary for atherosclerosis. More LDL particles (high LDL-C) = higher risk, period.
    • Evidence: Decades of epidemiological data, statin trials, and Mendelian randomization studies support LDL-C as a causal factor in CVD.
    • Concern: Even if LMHRs feel healthy now, they may be accumulating arterial damage that will manifest later.

    The "Context Matters" Camp

    • Position: LDL-C risk depends heavily on metabolic context. In the absence of insulin resistance, inflammation, and other risk factors, high LDL-C may be benign.
    • Evidence: Some populations (e.g., certain genetic variants, very elderly individuals) have high LDL-C without increased CVD risk.
    • Theory: The LMHR phenotype may represent a unique metabolic state where traditional risk factors don't apply.

    Current Clinical Dilemma

    For LMHRs:

    1. Continue keto and monitor closely with advanced testing?
    2. Modify the diet to lower LDL-C (e.g., add some carbs, reduce saturated fat)?
    3. Take statins to lower LDL-C while continuing keto?

    For Doctors:

    1. Follow standard guidelines and recommend LDL-C lowering regardless of context?
    2. Wait for more data while monitoring the patient closely?
    3. Individualize treatment based on the patient's overall risk profile?

    Bottom Line

    The question of CVD risk in LMHRs with high LDL-C is actively being researched and is far from settled. We're in a period of scientific uncertainty where:

    • Traditional lipidology says high LDL-C is dangerous.
    • Emerging research suggests the LMHR phenotype might be an exception.
    • Long-term outcome data is still being collected.

    For now, LMHRs and their doctors must make individualized decisions based on:

    • Advanced lipid testing (ApoB, particle size, Lp(a))
    • Imaging studies (calcium scores, CIMT)
    • Overall metabolic health
    • Personal risk tolerance
    • Family history

    The next 5-10 years of research will likely provide much clearer answers to this critical question.

  3. User

    why was the keto-cta study so controversial. what were the changes to its scope of study. and what were other experts in the field complaining about.

  4. Claude Assistant

    The Keto-CTA study became one of the most controversial nutrition studies in recent years, sparking heated debates across social media, academic circles, and the broader keto community. Here's what happened and why it caused such an uproar:


    What Was the Original Keto-CTA Study?

    The study, led by Dr. Luc Djousse at Harvard and Dr. Matthew Budoff at UCLA, was designed to examine whether a ketogenic diet increases coronary artery calcium (CAC) scores - a measure of arterial plaque buildup - in healthy adults over 12 months.

    Original Design:

    • Randomized controlled trial comparing keto vs. low-fat diet
    • Primary endpoint: Changes in coronary calcium scores
    • Duration: 12 months
    • Population: Healthy adults

    The Major Controversies and Changes

    1. Scope and Design Changes

    Original Plan → What Actually Happened:

    • Duration: 12 months → 6 months (cut in half)
    • Population: Healthy adults → Included people with existing cardiovascular disease
    • Primary Endpoint: Originally focused on calcium scores → Shifted emphasis to LDL-C changes
    • Sample Size: Reduced from original projections

    2. The "Lean Mass Hyper-Responder" Exclusion Controversy

    The Big Issue: The study protocol was modified to exclude participants whose LDL-C rose above 190 mg/dL on the keto diet.

    Why This Was Controversial:

    • This effectively excluded most Lean Mass Hyper-Responders (LMHRs) - the very population many wanted to study
    • LMHRs are the group with the most extreme LDL-C elevation on keto, making them the most relevant to study
    • Critics argued this was like studying "the effects of smoking while excluding heavy smokers"

    3. Mid-Study Protocol Changes

    What Happened:

    • Participants who developed high LDL-C were switched off keto mid-study for "safety reasons"
    • Some participants were given statins during the study
    • The study design was modified while it was ongoing

    Why This Was Problematic:

    • Changed the fundamental question from "What happens to arteries on long-term keto?" to "What happens when you do keto briefly then stop?"
    • Made it impossible to study the very phenomenon (high LDL-C on keto) that motivated the research

    What Experts Were Complaining About

    1. Dave Feldman and the Citizen Science Community

    Complaints:

    • The study excluded the most interesting population (LMHRs)
    • Protocol changes made the results meaningless for understanding keto's long-term effects
    • The study became more about confirming existing biases than discovering new knowledge

    2. Dr. David Diamond (University of South Florida)

    Complaints:

    • The study design was fundamentally flawed from a scientific methodology standpoint
    • Mid-study changes violated basic principles of clinical trial design
    • The results couldn't answer the original research question

    3. Dr. Paul Mason and Other Low-Carb Advocates

    Complaints:

    • The study appeared designed to show harm rather than objectively assess risk
    • Excluding high LDL-C responders was like "studying the safety of parachutes while excluding anyone who jumps from a plane"
    • The 6-month duration was too short to assess cardiovascular outcomes

    4. Academic Methodologists

    Complaints:

    • Selection bias: By excluding the highest responders, the study couldn't generalize to the full keto population
    • Endpoint switching: Changing primary outcomes mid-study is a major methodological red flag
    • Confounding variables: Adding statins and switching diets mid-study made results uninterpretable

    The Broader Scientific Issues

    1. Equipoise Problem

    • Equipoise means genuine uncertainty about which treatment is better
    • Critics argued the researchers didn't have true equipoise - they seemed to expect keto would be harmful
    • This may have influenced study design decisions

    2. Safety vs. Scientific Inquiry

    • The Dilemma: How do you study potentially risky interventions ethically?
    • The Problem: If you stop the intervention whenever the "risky" outcome occurs, you can't actually study whether that outcome leads to harm

    3. Regulatory and Institutional Pressures

    • IRB (Institutional Review Board) Pressure: Ethics committees may have pressured researchers to modify the protocol for "participant safety"
    • Liability Concerns: Universities and researchers may have been worried about liability if participants developed cardiovascular events

    What the Study Actually Showed (And Didn't Show)

    What It Showed:

    • LDL-C increased in many keto participants (no surprise)
    • Some participants had LDL-C increases that concerned investigators
    • Triglycerides decreased and HDL-C increased on keto (expected)

    What It DIDN'T Show:

    • Whether high LDL-C on keto actually leads to increased plaque formation
    • Long-term cardiovascular outcomes in LMHRs
    • Whether the LDL-C elevation in metabolically healthy individuals carries the same risk as in the general population

    The Aftermath and Lessons

    1. Study Design Challenges

    The controversy highlighted the difficulty of studying interventions that produce biomarker changes that appear risky by traditional standards but may not actually be harmful in context.

    2. Need for Better Research

    The controversy underscored the urgent need for:

    • Longer-term studies of keto in various populations
    • Studies specifically designed to include and follow LMHRs
    • Better understanding of when traditional risk factors apply vs. when they don't

    3. Scientific Communication Issues

    The study became a case study in how:

    • Protocol changes can undermine scientific credibility
    • Excluding the most relevant population can make results meaningless
    • Mid-study modifications can turn a potentially valuable study into a source of confusion rather than clarity

    Bottom Line

    The Keto-CTA study controversy wasn't just about keto - it was about fundamental principles of scientific methodology. By excluding the very population most relevant to the research question and making significant protocol changes mid-study, the researchers inadvertently created a study that satisfied no one and answered few questions.

    The controversy serves as a cautionary tale about the challenges of studying interventions that challenge conventional medical wisdom, and the importance of maintaining scientific rigor even when studying potentially controversial topics.

Responses were produced in different, uncontrolled contexts (system prompts, settings, prior turns). This is not a benchmark.